The observations were issued on completion of an inspection of the injectable facility of Eugia SEZ in Jadcherla by the ... to within the stipulated time,” Aurobindo Pharma said in a filing ...

and Derma Manufacturing facility located at Jadcherla, Mahabub Nagar District, Telangana, Aurobindo Pharma said in its release. The observations are procedural in nature. We will respond to the ...

Auditors uncovered “deficient” manufacturing equipment cleaning and storage controls during a visit last month to an Aurobindo Pharma Ltd. facility in Anakapalli, eastern India, according to a ...

Aurobindo, which is one of the largest generic drug makers, has halted some production at a key facility in India after U.S. inspectors found manufacturing problems, the latest such episode to ...

Aurobindo Pharma Q1 Results: Aurobindo Pharma released its April-June quarter results for fiscal 2023-24 (Q1FY24) on August 12, reporting a decline of 22.5 per cent in net profit at ₹540 crore ...